A computational molecular-discovery company combining physics-based simulation, machine learning and enterprise software.
Research candidate, not an investment rating. Identity and classification reflect a bounded evidence snapshot observed Jul 26, 2026.
Period ended Mar 31, 2026 · filed May 5, 2026
Period ended Dec 31, 2025 · filed Feb 25, 2026
Values are issuer-filed XBRL facts retrieved from SEC EDGAR. Missing concepts remain Unknown; non-GAAP values are not substituted.
AI roles are presented as source-anchored research interpretations. The document stream is regulator-primary, but a filing’s existence does not prove the claims contained inside it.
Role evidence, not a proprietary investment score
The issuer supplies data, evaluation or engineering capabilities used in AI development.
The annual filing and current results describe a commercial computational platform integrating physics, AI and machine learning.
AI is a material capability inside one or more current products or services.
The issuer also operates drug-discovery programs, so software evidence is kept separate from clinical-outcome uncertainty.
The annual filing and current results describe a commercial computational platform integrating physics, AI and machine learning.
The issuer also operates drug-discovery programs, so software evidence is kept separate from clinical-outcome uncertainty.
These sources support the issuer/listing and AI-exposure assessment. First-party evidence proves attribution—not independent truth.